1733 — Apex Biotechnology Cashflow Statement
0.000.00%
Last trade - 00:00
- TWD3.50bn
- TWD3.21bn
- TWD1.68bn
- 73
- 43
- 85
- 80
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 163 | 111 | 185 | 200 | 141 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 44.8 | 20.6 | 30.3 | 1.42 | 29.3 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 139 | 44.2 | -131 | -268 | -15.6 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | 463 | 281 | 180 | 26.6 | 230 |
Capital Expenditures | -56.8 | -48.3 | -30.2 | -40.7 | -25 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -76 | 127 | -4.83 | -0.711 | 2.48 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -133 | 78.8 | -35 | -41.4 | -22.5 |
Financing Cash Flow Items | -0.01 | 0.363 | -0.008 | 0.013 | -0.016 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 6.73 | -225 | -351 | -238 | -168 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 336 | 133 | -232 | -224 | 50.3 |